Find a Doctor
Frederick Locke, MD
Vice Chair, Department of Blood and Marrow Transplant and Cellular ImmunotherapyProgram Co-Leader, Immuno-Oncology
Sub Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy
Dr. Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Dr. Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. for several pivotal trials of anti-CD19 CARs for lymphoma. In addition, Dr. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. Dr. Locke graduated with a B.S. in Physiology from Michigan State University, and with an M.D. from Wayne State University. He stayed at Wayne State and the Detroit Medical Center for Internal Medicine residency training and then served as Chief Medical Resident at Detroit Receiving. Dr. Locke received Medical Oncology, clinical research, and laboratory research training at the University of Chicago. Dr. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy.
Education & Training
Start Year: 2012 End Year: Internal Research Grant Award, Sponsor: American Cancer Society
Start Year: 2015 End Year: Miles for Moffitt Scientist Award, Sponsor:
Start Year: 2015 End Year: Mentored Patient-Oriented Research Career Development Award, Sponsor: National Cancer Institute
Start Year: 2016 End Year: Cancer Clinical Investigator Team Leadership Award, Sponsor: National Cancer Institute
CLINICAL TRIAL 19724
CLINICAL TRIAL 20737
CLINICAL TRIAL 20578
CLINICAL TRIAL 20571
Title: Assessment of normal and malignant cells with respect to heterogeneous external cell-membrane levels of PS across patients naïve to, treated with or refractory to various approved agents.
12 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including: